Uses of botulinum toxin injection in medicine today
BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7228.161 (Published 15 January 2000) Cite this as: BMJ 2000;320:161- A Münchau, research fellow,
- K P Bhatia (K.Bhatia@ion.ucl.ac.uk), senior lecturer
- University Department of Clinical Neurology, Institute of Neurology, London WC1N 3BG
- Correspondence to: K P Bhatia
- Accepted 16 August 1999
Botulinum neurotoxin is produced by the anaerobic bacterium Clostridium botulinum. It is the most poisonous biological substance known. Very small amounts of botulinum toxin can lead to botulism, a descending paralysis with prominent bulbar symptoms and often affecting the autonomic nervous system. Botulism can occur in two ways. It can result from infection with bacterial spores that produce and release the toxin in the body—as in enteric infectious botulism, when the bacteria grow in the intestine, and in wound botulism, when the wound becomes infected. Alternatively, botulism occurs after ingestion of the toxin (food borne botulism).1
Botulism has been recognised since the early 19th century, and there was speculation about what caused the condition. In 1822 it was suggested that a “fatty acid” in sausages was the culprit,2 and this led to the term botulism (botulus being the Latin word for sausage). In 1897, Van Ermengen related botulism to a bacterial toxin.3
The discovery that botulinum toxin blocks neuromuscular transmission4 and thereby causes weakness laid the foundation for its development as a therapeutic tool. In 1981, the ophthalmologist Alan Scott pioneered treatment with botulinum toxin when he used it to treat strabismus.5 He paved the way for clinical research in many specialties.
Summary points
Botulinum toxin inhibits release of acetylcholine at the neuromuscular junction and in cholinergic sympathetic and parasympathetic neurones
Local injections of toxin weaken overactive muscles and control hypersecretion of glands supplied by cholinergic neurones
Botulinum toxin injections have an established role in some disorders of ocular motility
Botulinum toxin is the treatment of choice for focal dystonias such as torticollis and writer's cramp and for hemifacial spasm and may complement the management of spasticity
Local injections have also been shown to be beneficial in many other conditions including achalasia, chronic anal fissure, and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.